Pyridam Farma (PYFA) Facilitates International Training to Achieve Safer and More Effective Aesthetic and Neurology Medical Services
Jakarta, May 21, 2025 — PT Pyridam Farma Tbk (PYFA), known by the brand PYFAGROUP, once again demonstrated its commitment to patient safety and improving the quality of medical services in Indonesia. In May 2025, PYFA, through its business units PYFAESTHETIC & PYFARx, facilitated international training for Indonesian specialist doctors and general practitioners in two countries simultaneously—Italy and Vietnam—as a tangible form of the company’s support for the development of medical expertise in the aesthetic field.
“In line with our commitment, ‘Better Health, Better Life, Start with Us’, PYFA not only presents innovative products but also actively protects consumers by enhancing doctors’ capacities to remain relevant with global medical advancements,” said dr. Widjanarko Brotosaputro, Chief of Corporate Strategic Development Officer.
Through its PYFAESTHETIC business unit, the company organized the departure of seven Indonesian doctors, consisting of Dermatologists and Aesthetic Anti-Aging Medicine (AAM) doctors, to participate in the prestigious Cadaver Course in Verona, Italy, held from May 8–14, 2025. A Cadaver Course in the context of aesthetic medicine is a training where licensed medical professionals (such as dermatologists, plastic surgeons, and general aesthetic practitioners) perform dissections and injection simulations on preserved human cadaver heads and necks. The aim is to improve their anatomical knowledge of facial structures, including muscles, fat pads, ligaments, nerves, and blood vessels, and to enhance the safety and effectiveness of cosmetic treatments. This activity is the result of a collaboration between PYFAESTHETIC and our strategic partner, Love Cosmedical.
This Cadaver Course was guided by Prof. MD Roberto Amore as Course Director, a prominent Plastic Surgeon from Italy. He provided theoretical sessions on the first day, followed by hands-on sessions on the second day. The hands-on session is crucial for enhancing doctors’ understanding of facial structures, including muscles, fat pads, ligaments, nerves, and blood vessels—thus minimizing risks when performing aesthetic procedures.
“This training is very important for increasing confidence levels and patient safety. We learned firsthand which layers are safe and which need to be avoided during injection,” said dr. Deddy, Sp.DVE, one of the Cadaver Course participants from Indonesia.
In addition to participants from Indonesia, the training was also attended by experts from Europe, the Middle East, and Asia. This certainly strengthens the professional network of participants and opens avenues for cross-country collaboration.
In parallel, PYFARx also organized an Expert Meeting in Vietnam from May 8–11, 2025. A total of 18 Indonesian neurology specialists attended to explore new approaches in the management of ischemic stroke through neuroprotection therapy. This Expert Meeting in Vietnam represents a step towards Stroke Management Innovation and Global Collaboration.
This event collaborated with Polysan, a strategic partner from Russia, and featured keynote speaker Dr. Nguyen Thi Phuong Nga, a renowned neurologist from Vietnam. She presented material on the role of antihypoxia agents containing Succinic Acid, Riboflavin, Nicotinamide, and Inosine in stroke therapy.
“We were greatly helped by the clinical material and international research shared. This meeting opened new insights into the management of complex stroke cases,” said dr. Eko Arisetijono Marhaendraputro, Sp.S(K).
The event was also attended by practitioners from other countries such as Vietnam, Thailand, and Russia, positioning Indonesia as part of the global discussion on medical innovation.
Through this training program, PYFA reaffirms its role as a strategic partner in improving the quality of Indonesian healthcare professionals. With a comprehensive approach—from innovative products to clinical education—PYFA continues its efforts to realize international-standard medical services focused on patient safety.
“We believe that improving the quality of healthcare services must start with investing in human resources. Going forward, PYFA will expand the scope of this training to more countries and other medical fields,” concluded dr. Widjanarko.
About PYFAGROUP
PT Pyridam Farma Tbk (“PYFA”), known by the brand PYFAGROUP, is one of the publicly listed companies in the pharmaceutical sector, listed on the Indonesia Stock Exchange (Stock Code: PYFA). PYFA has various Business Units, including prescription drugs in various dosage forms such as tablets, capsules, creams, and injections. PYFA is the controlling shareholder of several of its subsidiaries, including PT Holi Pharma, located in Cimahi, West Java, PT Ethica Industri Farmasi, located…
Media Relations Contact:
Leilanie Nadia Kusuma
Website: www.pyfa.co.id
Email: corcomm@pyfa.co.id
